AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, David B., Harrington, Kimberly H., Cordeiro, James A., Leung, Ling Y., Putta, Santosh, Lacayo, Norman, Laszlo, George S., Gudgeon, Chelsea J., Hogge, Donna E., Hawtin, Rachael E., Cesano, Alessandra, Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539972/
https://www.ncbi.nlm.nih.gov/pubmed/23320091
http://dx.doi.org/10.1371/journal.pone.0053518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539972/
https://www.ncbi.nlm.nih.gov/pubmed/23320091
http://dx.doi.org/10.1371/journal.pone.0053518

Ejemplares similares